A novel transdermal therapy designed to modulate tumor pH called DYV800 helped make tumors substantially less acidic, restore T-cell activity, slow tumor growth, and improve survival in preclinical studies, according to a study using animal models of bladder cancer conducted by Dyve Biosciences, in collaboration with Moffitt Cancer Center.
FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.
